

# Statistical Methods for Addressing Missing Data in HIV/AIDS Surveillance Systems

## Secondary Analysis of the HPTN 065 Trial

Sahar Zangeneh, PhD

Vaccine and Infectious Disease Division  
Fred Hutchinson Cancer Research Center  
Seattle WA, U.S.A

May 17, 2018

- 1 HPTN 065 Study and National HIV Surveillance
- 2 Missing Data in HIV Surveillance
- 3 Conclusion and Future work

## 1 HPTN 065 Study and National HIV Surveillance

## 2 Missing Data in HIV Surveillance

## 3 Conclusion and Future work

Assess **feasibility** of a community-focused **enhanced test and link-to-care** strategy




- Improve performance of the HIV care cascade
- **Community randomized** trial with randomization at **care facilities**
- Used **surveillance data** for the **design** and **analysis**

Intervention cities: Bronx NY and Washington DC (38 care facilities total)

- **Control Groups:** Enhanced community outreach programs (ECOP)
- **Treatment Groups:** ECOP plus **financial incentives**

Non-intervention cities: Chicago, Philadelphia, Miami & Houston (ECOP underway)



# National HIV Surveillance System (NHSS)

**Collect** and **analyze** data on all persons living with HIV/AIDS (PLWHA) in the U.S.

- Monitor resources nationally and locally
- Improve program implementation in PLWHA

## Features

- Data available in aggregate form for HPTN 065
- Unified reporting systems
- **Dynamic data extraction:** quarterly data uploads


Monitor performance of the HIV care cascade

Use surveillance data to **estimate**

- Proportion of individuals **linked to HIV care** (LC)
- Proportion of individuals **virally suppressed** (VLS)

# Monitoring measured VLS in Philadelphia, PA.


Percentage of HIV+ People with Viral Suppression, by Data Upload Quarter: PA





# Monitoring measured VLS in Washington, DC.

Percentage of HIV+ People with Viral Suppression, by Data Upload Quarter: DC



1 HPTN 065 Study and National HIV Surveillance

2 Missing Data in HIV Surveillance

3 Conclusion and Future work

# Missingness in surveillance data

## Adherence

- Inferred VL suppression status

## Data quality and surveillance coverage

- Reporting lag
- Administrative missingness (common issue in EMR data)
- Lost specimens and/or records

- 1 Identify presence of bias
- 2 Correct biases in estimates when present




# Change point estimation (Tapsoba et al, 2018)

Identify data stabilization using observed **aggregated data**

- Dependence between observation at different time points
- Develop methods for inference

Predict value of estimand after the change-point, e.g. the “stabilized” value

# Bias-corrected value using change points



City	CP(q)	LC <sub>2011</sub> (%)
DC	3.00	82.13
Miami	3.20	53.54
Chicago	7.93	81.44
NY	3.74	89.68

# Missingness due to lack of full coverage

Address 'other' sources of missingness


For each person, observe a **sequence of lab measurements** collected **over time**

$$\hat{p}_{VLS,q} = \frac{\# \text{ of people } \text{virally suppressed} \text{ during quarter } q}{\# \text{ of people } \text{in care} \text{ during quarter } q}$$

Person  $i$  is **in care** during quarter  $q$

- Lab results in at least **two** of the past five quarters

# Individual-level data



For individuals **in care**, HPTN 065 defined

$$\text{VL status}_{iq} = \begin{cases} 1, & \text{if } VL_{iq} \text{ observed and } VL_{iq} < 400 \\ 1, & \text{if } VL_{iq} \text{ unobserved but } VL_{i(q-1)} < 400 \\ 0, & \text{if } VL_{iq} \text{ observed and } VL_{iq} > 400 \\ 0, & \text{if } VL_{iq} \text{ unobserved and } VL_{i(q-1)} > 400 \\ 0, & \text{otherwise} \end{cases} \quad (1)$$

Assume all missingness to be driven by non-adherence



# Missing data in measurements

For individuals **in care**, we propose


$$\text{VL status}_{iq} = \begin{cases} 1, & \text{if } VL_{iq} \text{ observed and } VL_{iq} < 400 \\ 1, & \text{if } VL_{iq} \text{ unobserved but } VL_{i(q-1)} < 400 \\ 0, & \text{if } VL_{iq} \text{ observed and } VL_{iq} > 400 \\ 0, & \text{if } VL_{iq} \text{ unobserved and } VL_{i(q-1)} > 400 \\ 0, & \text{otherwise} \end{cases} \quad (2)$$

Could be 0 or 1 with probability depending on coverage of lab measurements

Missingness driven by **non-adherence** or **non-coverage**

# Simulation study

If we knew the true coverage of lab measurements in surveillance



Use auxiliary data to estimate coverage of lab measurements in surveillance

# Estimating surveillance coverage

Use sample survey data from the **Medical Monitoring Project (MMP)**

- Better coverage of lab measurements
- Restricted to 400 individuals in each jurisdiction

Need individual level data

- 1 Two-dimensional matching
- 2 **Dual-system estimation** to estimate coverage of labs

Use computer-simulated data, and request analysis using real data

1 HPTN 065 Study and National HIV Surveillance

2 Missing Data in HIV Surveillance

3 Conclusion and Future work

Data quality raises challenges, beyond what was anticipated during design stage

Many issues leading to missingness

Addressed two ways of mitigating bias from missing measurements

Second project is ongoing

- Developing software for estimating surveillance coverage
- Developing method to quantify the uncertainty

## Fred Hutch

- Deborah Donnell
- Ying Chen
- Jean de Dieu Tapsoba
- CY Wang

This work was partially supported by the National Institutes of Health grant MH105857. The HIV Prevention Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068619, UM1AI068613, UM1AI1068617), with co-funding from the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health.

## DOH Philadelphia

- Kathleen Brady
- Tanner Nassau
- Antonios Mashas

## DOH New York

- Qiang Xia
- Lucia Torian